Skip to main content
. Author manuscript; available in PMC: 2022 May 17.
Published in final edited form as: Epilepsia. 2021 Jul 15;62(9):e140–e146. doi: 10.1111/epi.16997

Table 1.

Patient demographics and baseline characteristics

Characteristics Cases (N=43) Controls (N=43) p value
Age, year
Median (IQR) 38 (30-45) 39 (28-43) 0.7623
Sex, n (%)
 Female 13 (30.23) 13 (30.23) > 0.99
Duration of epilepsy, y
Median (IQR) 25 (12-37) 9 (4-23) < 0.0001
Type of epilepsy, n (%) 0.757
  Focal 32 (74.41) 34 (79.06)
  Multifocal 6 (13.95) 3 (6.97)
  Generalized 3 (6.97) 4 (9.30)
  Focal + generalized 1 (2.32) 0 (0)
  Unclear 1 (2.32) 2 (4.65)
Putative epileptogenic zone, n (%) 0.055
  Temporal 15 (34.88) 22 (51.16)
  Extratemporal 20 (46.51) 7 (16.27)
  Generalized 3 (6.97) 4 (9.30)
  Temporal + extratemporal 3 (6.97) 4 (9.30)
  Unclear 3 (6.97) 6 (13.95)
History of generalized convulsive seizure, n (%) 42 (97.67) 38 (88.37) 0.20
HCVR slope, L/min/mm Hg
Median (IQR) 1.17 (0.57-1.99) 1.65 (1.26-2.24) 0.0402
BMI, kg/m2
Median (IQR) 27.4 (24.2-35.2) 26.9 (23.5-32.6) 0.4268
Duration of VNS implant, y
Median (IQR) 6.0 (1.5-10.0) NA NA
Stimulation current per day, mA seconds
Median (IQR) 203 (49-354) NA NA
No. of AEDs at HCVR testing, n
Median (IQR) 2 (2-3) 2 (1-2) 0.0132
No. of AEDs tried lifetime, n
Median (IQR) 8 (5-10) 3 (2-5) < 0.0001
Use of SSRI/SNRI
Number (%) 11 (25.6) 11 (25.6) > 0.99
History of OSA
Number (%) 6 (14.3) 8 (19.1) 0.5582
History of depression, Number (%) 20 (46.5) 20 (47.6) 0.9185

Abbreviations: BMI (Body mass index); AED (anti-epileptic drug); SSRI/SNRI (selective serotonergic reuptake inhibitor and serotonin-norepinephrine reuptake inhibitors); OSA (obstructive sleep apnea); IQR (Interquartile range)

Continuous variables were compared using the Wilcoxon rank-sum test. Categorical variables were compared using Pearson’s chi-square test and Fisher’s exact test as appropriate.

Count outcome variables used Poisson regression.